Background: Diffuse intrinsic pontine glioma (DIPG) is a high-grade brainstem glioma of children with dismal prognosis. There is no single unifying model about the cell of origin of DIPGs. Proliferating cells in the developing human and mouse pons, the site of DIPGs, express neural stem/progenitor cell (NPC) markers, including Sox2, nestin, vimentin, Olig2, and glial fibrillary acidic protein, in an overlapping and non-overlapping manner, suggesting progenitor cell heterogeneity in the pons. It is thought that during a restricted window of postnatal pons development, a differentiation block caused by genetic/epigenetic changes leads to unrestrained progenitor proliferation and DIPG development. Nearly 80% of DIPGs harbor a mutation in the H3F3A or the related HIST1H3B gene. Supporting the impaired differentiation model, NPCs derived from human induced pluripotent stem cells expressing the H3F3A mutation showed complete differentiation block. However, the mechanisms regulating an altered differentiation program in DIPG are unknown. Methods: We established syngeneic serum-dependent and independent primary DIPG lines, performed molecular characterization of DIPG lines in vitro and in an orthotopic xenograft model, and used small hairpin RNA to examine Olig2 function in DIPG. Results: The transcription factor Olig2 is highly expressed in 70%-80% of DIPGs. Here we report that Olig2 expression and DIPG differentiation are mutually exclusive events in vitro, and only DIPG cells that retained Olig2 in vitro formed robust Olig2-positive brainstem glioma with 100% penetrance in a xenograft model. Conclusion: Our results indicate Olig2 as an onco-requisite factor in DIPG and propose investigation of Olig2 target genes as novel candidates in DIPG therapy.
Background: Diffuse intrinsic pontine glioma (DIPG) is a high-grade brainstem glioma of children with dismal prognosis. There is no single unifying model about the cell of origin of DIPGs. Proliferating cells in the developing human and mouse pons, the site of DIPGs, express neural stem/progenitor cell (NPC) markers, including Sox2, nestin, vimentin, Olig2, and glial fibrillary acidic protein, in an overlapping and non-overlapping manner, suggesting progenitor cell heterogeneity in the pons. It is thought that during a restricted window of postnatal pons development, a differentiation block caused by genetic/epigenetic changes leads to unrestrained progenitor proliferation and DIPG development. Nearly 80% of DIPGs harbor a mutation in the H3F3A or the related HIST1H3B gene. Supporting the impaired differentiation model, NPCs derived from human induced pluripotent stem cells expressing the H3F3A mutation showed complete differentiation block. However, the mechanisms regulating an altered differentiation program in DIPG are unknown. Methods: We established syngeneic serum-dependent and independent primary DIPG lines, performed molecular characterization of DIPG lines in vitro and in an orthotopic xenograft model, and used small hairpin RNA to examine Olig2 function in DIPG. Results: The transcription factor Olig2 is highly expressed in 70%-80% of DIPGs. Here we report that Olig2 expression and DIPG differentiation are mutually exclusive events in vitro, and only DIPG cells that retained Olig2 in vitro formed robust Olig2-positive brainstem glioma with 100% penetrance in a xenograft model. Conclusion: Our results indicate Olig2 as an onco-requisite factor in DIPG and propose investigation of Olig2 target genes as novel candidates in DIPG therapy.
Authors: Michelle Monje; Siddhartha S Mitra; Morgan E Freret; Tal B Raveh; James Kim; Marilyn Masek; Joanne L Attema; Gordon Li; Terri Haddix; Michael S B Edwards; Paul G Fisher; Irving L Weissman; David H Rowitch; Hannes Vogel; Albert J Wong; Philip A Beachy Journal: Proc Natl Acad Sci U S A Date: 2011-03-01 Impact factor: 11.205
Authors: P G Fisher; S N Breiter; B S Carson; M D Wharam; J A Williams; J D Weingart; D R Foer; P T Goldthwaite; T Tihan; P C Burger Journal: Cancer Date: 2000-10-01 Impact factor: 6.860
Authors: Erica L Jackson; Jose Manuel Garcia-Verdugo; Sara Gil-Perotin; Monica Roy; Alfredo Quinones-Hinojosa; Scott VandenBerg; Arturo Alvarez-Buylla Journal: Neuron Date: 2006-07-20 Impact factor: 17.173
Authors: Shwetal Mehta; Emmanuelle Huillard; Santosh Kesari; Cecile L Maire; Diane Golebiowski; Emily P Harrington; John A Alberta; Michael F Kane; Matthew Theisen; Keith L Ligon; David H Rowitch; Charles D Stiles Journal: Cancer Cell Date: 2011-03-08 Impact factor: 31.743
Authors: Keith L Ligon; John A Alberta; Alvin T Kho; Jennifer Weiss; Mary R Kwaan; Catherine L Nutt; David N Louis; Charles D Stiles; David H Rowitch Journal: J Neuropathol Exp Neurol Date: 2004-05 Impact factor: 3.685
Authors: Zhenhua Xu; Najiba Murad; Daniel Malawsky; Ran Tao; Samuel Rivero-Hinojosa; Dörthe Holdhof; Ulrich Schüller; Peng Zhang; Christopher Lazarski; Brian R Rood; Roger Packer; Timothy Gershon; Yanxin Pei Journal: Clin Cancer Res Date: 2022-10-03 Impact factor: 13.801
Authors: Flor Mendez; Padma Kadiyala; Felipe J Nunez; Stephen Carney; Fernando M Nunez; Jessica C Gauss; Ramya Ravindran; Sheeba Pawar; Marta Edwards; Maria Belen Garcia-Fabiani; Santiago Haase; Pedro R Lowenstein; Maria G Castro Journal: Clin Cancer Res Date: 2020-04-24 Impact factor: 12.531
Authors: Felix Behling; Alonso Barrantes-Freer; Carl Ludwig Behnes; Florian Stockhammer; Veit Rohde; Antonia Adel-Horowski; Odir Antonio Rodríguez-Villagra; Miguel Angel Barboza; Wolfgang Brück; Ulrich Lehmann; Christine Stadelmann; Christian Hartmann Journal: PLoS One Date: 2020-03-11 Impact factor: 3.752